Based on data from the past 90 days ending February 07, 2026, Apogee Therapeutics's three largest insider shareholders are Director Nimish P Shah (1.75Mn shares), Chief Executive Officer Michael Thomas Henderson (1.19Mn shares), Director Funds Management Llc Fairmount (298.65K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Nimish P Shah | 1,750,000 | 17 Jul, 2023 | |
| Michael Thomas Henderson | Chief Executive Officer | 1,192,987 | 16 Jan, 2026 |
| Funds Management Llc Fairmount | 298,647 | 22 Jan, 2026 | |
| Carl Dambkowski | Chief Medical Officer | 211,148 | 04 Feb, 2026 |
| Jane Henderson | Chief Financial Officer | 183,371 | 04 Feb, 2026 |
| Mark C. Mckenna | 20,000 | 16 Dec, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | D | 1,299 | $66.85 | 211,448 | D | S |
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | D | 200 | $68.94 | 211,148 | D | S |
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | D | 1,420 | $65.83 | 212,747 | D | S |
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | A | 4,125 | $22.86 | 216,648 | D | M |
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | D | 100 | $67.88 | 211,348 | D | S |
| 04 Feb, 2026 | Carl Dambkowski | Common Stock | D | 2,481 | $64.88 | 214,167 | D | S |
| 02 Feb, 2026 | Jane Henderson | Common Stock | D | 792 | $65.21 | 184,579 | D | S |
| 02 Feb, 2026 | Jane Henderson | Common Stock | D | 1,108 | $66.15 | 183,471 | D | S |
| 02 Feb, 2026 | Jane Henderson | Common Stock | D | 100 | $66.89 | 183,371 | D | S |
| 22 Jan, 2026 | Funds Management Llc Fairmount | Common Stock | D | 1,750,000 | $76.30 | 298,647 | I | S |
| 14 Jan, 2026 | Michael Thomas Henderson | Common Stock | D | 8,476 | $79.82 | 1,203,071 | D | S |
| 14 Jan, 2026 | Michael Thomas Henderson | Common Stock | D | 1,854 | $82.41 | 1,198,843 | D | S |
| 14 Jan, 2026 | Michael Thomas Henderson | Common Stock | D | 2,374 | $81.00 | 1,200,697 | D | S |
| 14 Jan, 2026 | Michael Thomas Henderson | Common Stock | D | 1,440 | $78.64 | 1,211,547 | D | S |
| 14 Jan, 2026 | Michael Thomas Henderson | Common Stock | D | 470 | $83.79 | 1,192,987 | D | S |
| 14 Jan, 2026 | Michael Thomas Henderson | Common Stock | D | 5,386 | $83.16 | 1,193,457 | D | S |
| 07 Jan, 2026 | Carl Dambkowski | Common Stock | D | 100 | $80.06 | 212,523 | D | S |
| 07 Jan, 2026 | Carl Dambkowski | Common Stock | D | 14,820 | $77.90 | 213,449 | D | S |
| 07 Jan, 2026 | Carl Dambkowski | Common Stock | D | 826 | $79.04 | 212,623 | D | S |
| 07 Jan, 2026 | Carl Dambkowski | Common Stock | A | 14,025 | $22.86 | 231,223 | D | M |